InMode Ltd.

What they do

InMode designs, develops, and sells radiofrequency-based medical devices for aesthetic and surgical applications, including body contouring, skin tightening, and gynecological procedures. The company's products are used by physicians and aesthetic practitioners. Its portfolio includes a range of platforms that combine energy-based technologies with minimally invasive handpieces.

Revenue drivers

• Aesthetic medical devices — Core product line generating the majority of revenue, sold globally to aesthetic physicians and clinics.
• Minimally invasive platforms — A growing segment of the business, includes products like the EmpowerRF family and V系列, which are priced higher than non-invasive devices.
• Recurring consumables and services — Includes single-use handpieces and service contracts, which provide ongoing revenue after initial device sale.
• International markets — Sales outside North America contribute significantly, with the company expanding in Europe, Asia-Pacific, and Latin America.

Recent performance

Revenue declined from $394.8 million in 2024 to $370.5 million in 2025, a drop of about 6%. Net income fell sharply to $93.8 million from $181.3 million in 2024. Diluted EPS decreased to $1.43 from $2.25. Operating cash flow also declined to $85.3 million from $132.7 million. The balance sheet remains strong with $302.5 million in cash, $83.2 million in total liabilities, and $683.2 million in shareholder equity.

Strategy

Management is focused on product innovation, particularly in minimally invasive platforms, and expanding into new geographic markets. The company continues to invest in research and development to bring new technologies to market. In 2025, InMode repurchased shares, reducing diluted share count. The strategy also emphasizes maintaining a lean cost structure and high operating margins.

Risks

• Regulatory clearance risk — Delays or failures in obtaining and maintaining regulatory approvals could limit product launches and market access.
• Demand softness — Recent revenue declines suggest reduced customer spending on capital equipment, which may persist.
• Competitive pressure — The aesthetic device market is competitive, with new entrants and technologies potentially eroding market share.
• Geopolitical and economic exposure — Operations in Israel and sales across global markets expose the company to regional instability and currency fluctuations.

Outlook

Management has not provided specific forward revenue or earnings guidance in the filing. They expect continued innovation to drive future growth, with a pipeline of new products planned. The company is also focused on expanding its customer base beyond traditional aesthetic practitioners. Cash generation is expected to remain positive, supporting ongoing share repurchases and strategic investments.